What is ATRA stock price today?

ATRA (Atara Biotherapeutics Inc) stock is trading at $5.02 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ATRA stock going up or down today?

ATRA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ATRA stock now?

The decision to buy ATRA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ATRA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ATRA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ATRA stock overvalued or undervalued?

ATRA currently trades at a P/E ratio of 2.05, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if ATRA is fairly priced.

What is ATRA's P/E ratio?

ATRA has a price-to-earnings (P/E) ratio of 2.05, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ATRA's market cap?

ATRA (Atara Biotherapeutics Inc) has a market capitalization of $0.04 billion, making it a small-cap stock.

What is ATRA's price to book ratio?

ATRA trades at a price-to-book (P/B) ratio of 16.14, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ATRA pay dividends?

ATRA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ATRA's dividend yield?

ATRA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ATRA stock a good long-term investment?

ATRA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ATRA's revenue growth rate?

ATRA has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ATRA is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in ATRA?

Key risks for ATRA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ATRA compare to its competitors?

Compare ATRA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ATRA's performance and positioning.

What is ATRA's stock price target for 2026?

Our AI model provides price targets for ATRA based on fundamental analysis: Bull case $6.53 (+30%), Base case $5.77 (+15%), Bear case $4.52 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ATRA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ATRA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ATRA's next earnings report?

ATRA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ATRA - Atara Biotherapeutics Inc

NYSE * Health Care * Biotechnology

$5.02

$-0.25 (-4.74%)

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA Key Statistics

Market Cap

$43.10M

P/E Ratio

2.05

P/B Ratio

16.14

EPS

$2.57

Revenue Growth

-1.0%

Profit Margin

0.3%

Employees

How ATRA Compares to Peers

ATRA has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

ATRA is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ATRA(This stock)	$43.10M	2.1	-1%	0.3%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Atara Biotherapeutics Inc Company Information

Headquarters: California; U.S.A
Website: www.atarabio.com
Sector: Health Care
Industry: Biotechnology

ATRA - Atara Biotherapeutics Inc

About Atara Biotherapeutics Inc

ATRA Key Statistics

How ATRA Compares to Peers

Atara Biotherapeutics Inc Company Information

ATRA Lician Score

ATRA Financial Snowflake

Upcoming Events for ATRA